Curriculum vitae Name - Evangelisches Klinikum Niederrhein

Curriculum vitae
Name:
Prof. Dr. med. Jörg Friedrich Schlaak
geb. 2.7.1963 in Kiel
Beruflicher Werdegang:
5/1982: Abitur, Gymnasium Kronshagen
10/1982-10/1988: Studium der Medizin, Christian Albrechts-Universität Kiel
2/1989-10/1989: Arzt im Praktikum in der Inneren Abteilung des Kreiskrankenhauses des Kreises
Plön in Preetz
3/1989: Promotion zum Doktor der Medizin in Kiel, Thema: "Über die Wirkung versch.
Überträgersubstanzen an der Mesenterialarterie des Meerschweinchens"
1/1990-10/1990: Arzt im Praktikum an der I. Medizinischen Klinik und Poliklinik der Johannes
Gutenberg Universität Mainz
11/1990: Approbation als Arzt und Beginn der Tätigkeit als Assistenzarzt an der I. Med.
Klinik und Poliklinik der Universität Mainz
11/1996: Facharzt für Innere Medizin
1/1998: Oberarzt der I. Med. Klinik und Poliklinik der Universität Mainz
5/2000: Erwerb der Zusatzbezeichnung Gastroenterologie
11/2001: Oberarzt der Klinik für Gastroenterologie und Hepatologie des
Universitätsklinikums Essen (Direktor: Prof. Dr. med. G. Gerken)
6/2004: Stellvertretender Direktor der Klinik für Gastroenterologie und Hepatologie des
Universitätsklinikums Essen
11/2011: Initiator und Koordinator des Lebertumorzentrums Essen
1/2013: Chefarzt der Medizinischen Klinik I am Evang. Klinikum Niederrhein Duisburg
Klinische Schwerpunkte: Hepatologie incl. Transplantationshepatologie, Gastroenterologie,
Endoskopie, Infektiologie, primäre und sekundäre Lebertumoren
Wissenschaftlicher Werdegang:
1/1991-12/1991: Ausbildung auf dem Gebiet der zellulären und molekularbiologischen
Immunologie im Labor von Prof. Bernhard Fleischer
1/1992-b.a.w.:
Aufbau eines eigenen Labors
12/1993: Beginn der Förderung des Projektes SCHL377/1-1 (Immunregulation bei
Lebererkrankungen) durch die Deutsche Forschungsgemeinschaft
3/1996: Fortsetzung der Förderung des Projektes SCHL377/1-2 durch die Deutsche
Forschungsgemeinschaft

9/1997: Fortsetzung der Förderung des Projektes SCHL377/1-4 durch die Deutsche
Forschungsgemeinschaft
2-11/1997: Verfahren zur Erlangung der Venia legendi im Fach Innere Medizin
12/1997: Antrittsvorlesung an der medizinischen Fakultät der Johannes Gutenberg-
Universität Mainz mit dem Thema: “Von der Pathophysiologie zu neuen
Konzepten in der Therapie chronischer Virushepatitiden”
1-12/2000: Mitglied im Sonderforschungsbereich 490 “Invasion und Persistenz bei
Infektionen” (Projekt A5)
2/2000-10/2001: Gastwissenschaftler am Imperial College of Science, Technology and Medicine
(Professor Howard C. Thomas) und Imperial Cancer Research Fund (Professor
Ian Kerr), London
11/2000-10/2001: Förderung durch ein Feodor-Lynen Stipendium der Alexander von Humboldt-
Stiftung
5/2003: Beginn der Förderung des Projektes SCHL377/2-1 (Interferonsignalwege der
Leber) durch die Deutsche Forschungsgemeinschaft
12/2003: Beginn der Förderung des Projektes SCHL377/3-1 (Klinische Zentraleinheit der
KFO 117) durch die Deutsche Forschungsgemeinschaft
8/2004: Beginn der Förderung des Projektes LU 669/5-1 (In vivo Analyse der Bedeutung
immunmodulierender und antiviraler Gene bei akuter und chronischer Woodchuck
Hepatitis Virus Infektion) durch die Deutsche Forschungsgemeinschaft,
Koantragsteller mit Herrn PD Dr. M. Lu, Institut für Virologie des
Universitätsklinikums Essen
12/2004: Ernennung zum Universitätsprofessor (C3) für das Fach
Transplantationshepatologie, Leiter der Klinischen Forschergruppe „Optimierung
der Leberlebendspende“ (KFO117) der Deutschen Forschungsgemeinschaft
5/2006: Beginn der Förderung des Projektes SCHL377/6-1 (Regulation und Modulation
der Leberregeneration in einem Rattenmodell der Leberlebendspende) durch die
Deutsche Forschungsgemeinschaft
6/2007 Förderung des DFG Projektes SCHL377/6-2 im Rahmen der KFO117
5/2009: Förderung des DFG-Projekts SCHL377/2-4
5/2009: Förderung des Projekts B4 des Transregio SFBs TRR 60
1/2011: Initiator und Korrdinator des PROFILE-Konsortiums
Wissenschaftliche Schwerpunkte:
Pathogenese chronischer viraler Lebererkrankungen,
Transplantationshepatologie, HCC, Biomarker
Editorial Boards: PLoS One, Journal of Gastroenterology and Hepatology Research, Hepatitis
Research and Treatment, World Journal of Gastroenterology

II. Originalarbeiten
1. J. F. Schlaak, E. Hermann, M. Ringhoffer, P. Probst, H. Gallati, K.-H. Meyer zum Büschenfelde, B. Fleischer
(1992): Predominance of Th1-type T cells in synovial fluid of patients with Yersinia-induced reactive arthritis. Eur.
J. Immunol. 22, 2771-2776. IF: 5,103
2. J. F. Schlaak, H. Löhr, H. Gallati, K.-H. Meyer zum Büschenfelde, B. Fleischer (1993): Analysis of the in vitro
cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis. Clin. Exp. Immunol. 94,
168-173. IF: 3,360
3. J. F. Schlaak, E. Hermann, H. Gallati, K.-H. Meyer zum Büschenfelde, B. Fleischer (1994): Differential effects of
IL-10 on proliferation and cytokine production of human γ/δ and α/β T cells. Scand. J. Immunol. 39, 209-215. IF:
2,230
4. J. F. Schlaak, E. Schmitt, C. Hüls, K.-H. Meyer zum Büschenfelde, B. Fleischer (1994): A sensitive and specific
bioassay for the detection of human interleukin-10. J. Immunol. Methods. 168, 49-54. IF: 2,203
5. J. F. Schlaak, P. Nieder, K.-H. Meyer zum Büschenfelde, B. Fleischer (1994): Human T helper cells reactive
with somatic bacterial antigens belong to the Th1 subset. Med. Microbiol. Immunol. 183, 169-175. IF: 3,833
6. J. F. Schlaak, M. Buslau, W. Jochum, E. Hermann, M. Girndt, H. Gallati, K.-H. Meyer zum Büschenfelde, B.
Fleischer (1994): T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Invest. Dermatol. 102[2],
145-149. IF: 6,314
7. H. F. Löhr, J. F. Schlaak, G. Gerken, B. Fleischer, H.-P. Dienes, K.-H. Meyer zum Büschenfelde (1994):
Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients
with chronic hepatitis of different etiology. Liver. 14, 161-166. IF: 3,824
8. C. Claus, J. F. Schlaak, M. Dittmayer, K.-H. Meyer zum Büschenfelde, W. Dippold. Inhibition of antibodyinduced
proliferation of human CD8 + T cells by CD16 + natural killer cells (1994): Eur. J. Immunol. 24, 1208-
1212. IF: 5,103
9. J. F. Schlaak, A. Schwarting, P. Knolle, K.-H. Meyer zum Büschenfelde, W. Mayet (1995): Effects of Th1 and
Th2 cytokines on cytokine production and ICAM-1 expressionon synovial fibroblasts. Ann. Rheum. Dis. 54[7],
560-565. IF: 8,727
10. J. F. Schlaak, C. Clauss, K.-H. Meyer zum Büschenfelde, W. Dippold (1995): Anti-GD3 antibodies are potent
activators of human γ/δ and α/β positive T cells. Scand. J. Immunol. 41[5], 474-480. IF: 2,230
11. P. Knolle, J. F. Schlaak, A. Uhrig, P. Kempf, K.-H. Meyer zum Büschenfelde, G. Gerken (1995): Human Kupffer
cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J. Hepatol. 22[2], 226-229. IF: 9,264
12. H. F. Löhr, J. F. Schlaak, H. P. Dienes, J. Lorenz, K.-H. Meyer zum Büschenfelde, G. Gerken (1995): Liver
cirrhosis associated with heterozygous alpha-1-antitrypsin deficiency type Pi MS and autoimmune features.
Digestion. 56[1], 41-45. IF: 2,046
13. M. Girndt, H. Köhler, E. Schiedhelm-Weick, J. F. Schlaak, K.-H. Meyer zum Büschenfelde, B. Fleischer (1995):
Production of interleukin-6, tumor necrosis factor α and interleukin-10 in vitro correlates with the clinical immune
defect in chronic hemodialysis patients. Kid. International. 47[2], 559-565. IF: 6,606
14. H. F. Löhr, W. Weber, J. F. Schlaak, B. Goergen, K.-H. Meyer zum Büschenfelde, G. Gerken (1995):
Proliferative response of CD4 + T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis
B e-minus hepatitis B virus mutants. Hepatology. 22[1], 61-68. IF: 11,665
15. H. F. Löhr, J. F. Schlaak, G. Kollmannsperger, H.-P. Dienes, K.-H. Meyer zum Büschenfelde, G. Gerken (1996):
Liver-infiltrating and circulating CD4 + T cells in chronic hepatitis C: immunodominant epitopes, HLA-restriction
and functional significance. Liver. 16, 174-182. IF: 3,824
16. J. F. Schlaak, I. Pfers, K.-H. Meyer zum Büschenfelde, E. Märker-Hermann (1996): Different cytokine profiles in
the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin.
Exp. Rheumatol. 14, 155-162. IF: 2,148
17. G. Zissel, J. F. Schlaak, M. Schlaak, J. Müller-Quernheim (1996): Regulation of cytokine release by alveolar
macrophages treated with interleukin-4, interleukin-10, or transforming growth factor beta. Eur. Cytokine Netw.
7[1], 59-66. IF : 1,726

18. M. Heike, J. F. Schlaak, H. Schulze-Bergkamen, S. Heyl, W. Herr, U. Schmitt, P. M. Schneider, K.-H. Meyer
zum Büschenfelde (1996): Specificities and functions of CD4 + HLA class II-restricted T cell clones against a
human sarcoma: evidence for several recognized antigens. J. Immunol. 156[6], 2205-2213. IF: 5,788
19. A. Schwarting, J. F. Schlaak, J. Lotz, I. Pfers, K.-H. Meyer zum Büschenfelde, W. Mayet (1996): Endothelin-1
modulates the expression of adhesion molecules on synovial fibroblast-like synovial cell (FLS). Scand. J.
Rheumatol. 25, 246-256. IF: 2,507
20. G. Zissel, J. Homolka, J. F. Schlaak, M. Schlaak, J. Müller-Quernheim (1996): Anti-inflammatory cytokine
release by alveolar macrophages in pulmonary sarcoidosis. Am. J. Resp. Crit. Care Med. 154, 713-719. IF:
10,689
21. H. F. Löhr, J. F. Schlaak, A. W. Lohse, W. O. Böcher, M. Arenz, G. Gerken, K.-H. Meyer zum Büschenfelde
(1996): Autoreactive CD4 + LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive
autoimmune hepatitis. Hepatology. 24, 1416-1421. IF: 11,665
22. M. Heike, J. F. Schlaak, S. Heyl, H. Schulze-Bergkamen, U. Schmitt, K.-H. Meyer zum Büschenfelde (1997):
Contrary roles of IL-4 and IL-12 on IL-10 production and proliferation of human tumour reactive T cells. Scand. J.
Immunol. 45[2], 221-226. IF: 2,230
23. A. Schwarting, J. F. Schlaak, E. Wandel, K.-H. Meyer zum Büschenfelde, W. Mayet (1997): Human renal tubular
epithelial cells as target cells for antibodies to proteinase 3 (c-ANCA). Nephrol. Dial. Transplant. 12[5], 916-
923. IF: 3,306
24. J. F. Schlaak, M. Trippler, I. Ernst, K.-H. Meyer zum Büschenfelde, G. Gerken (1997): Chronic hepatitis C: The
viral load per liver cell before treatment as a new marker to predict long-term response to IFN-α therapy. J.
Hepatol. 27[5], 917-921. IF: 9,264
25. K. Barbulescu, C. Becker, J. F. Schlaak, E. Schmitt, K.-H. Meyer zum Büschenfelde (1998): Cutting edge: IL-12
and IL-18 differentially regulate the transcriptional activity of the human IFN-γ promoter in primary CD4 + T
lymphocytes. J. Immunol. 160[8], 3642-3647. IF: 5,788
26. J. F. Schlaak, T. Pitz, H.F. Löhr, G. Gerken, K.-H. Meyer zum Büschenfelde (1998): IL-12 enhances deficient
HCV-antigen induced Th1-type immune response of peripheral blood mononuclear cells. J. Med. Virol. 56, 112-
117. IF: 2,820
27. H. F. Löhr, S. Krug, W. Herr, S. Weyer, J. F. Schlaak, T. Wölfel, G. Gerken, K.-H. Meyer zum Büschenfelde
(1998): Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic
hepatitis B. Liver. 18, 405-413. IF: 3,824
28. K. Hildner, E. Märker-Hermann, J. F. Schlaak, C. Becker, T. Germann, E. Schmitt, K.-H. Meyer zum
Büschenfelde, M. F. Neurath (1998): Azathioprine, mycophenolate mofetil and methotrexate specifically
modulate cytokine production by T cells. Ann. New York Acad. Sci. USA. 859, 204-207. IF: 3,155
29. M. F. Neurath, R. Wanitschke, M. Peters, K. Hildner, R. Tufan, K.-H. Meyer zum Büschenfelde, J. F. Schlaak
(1998). Mycophenolate mofetil for treatment of active inflammatory bowel disease. Clinical and immunological
studies. Ann. New York Acad. Sci. USA. 859, 315-318. IF: 3,155
30. H. F. Löhr, G. Gerken, M. Roth, S. Weyer, J. F. Schlaak, K.-H. Meyer zum Büschenfelde (1998): The cellular
immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may
determine the therapy outcome. J. Hepatol. 29[4], 524-532. IF: 9,264
31. W. O. Böcher, S. Herzog-Hauff, J. F. Schlaak, K.-H. Meyer zum Büschenfelde, H. F. Löhr (1999): Kinetics of
hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination:
stimulation of the in vitro antibody response by interferon gamma. Hepatology. 29[1], 238-244. IF: 11,665
32. M. F. Neurath, K. Hildner, C. Becker, J. F. Schlaak, K. Barbulescu, T. Germann, E. Schmitt, P. Schirmacher, S.
Haralambous, M. Pasparakis, G. Kollias, E. Märker-Hermann (1999): Methotrexate specifically modulates
cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for
methotrexate-mediated immunosuppression. Clin. Exp. Immunol. 115[1], 42-55. IF: 3,360
33. J. F. Schlaak, G. Tully, H.F. Löhr, G. Gerken, K.-H. Meyer zum Büschenfelde (1999): HBV-specific immune
defect in chronic hepatitis B is correlated with a dysregulation of pro- and antiinflammatory cytokines. Clin. Exp.
Immunol. 115, 508-514. IF: 3,360
34. M. F. Neurath, R. Wanitschke, M. Peters, F. Krummenauer, K.-H. Meyer zum Büschenfelde, J. F. Schlaak
(1999): Randomised trial of mycophenolate mofetil for treatment of chronic active Crohn´s disease. Gut. 44[5],
625-628. IF: 10,111

35. J. F. Schlaak, G. Tully, H. F. Löhr, G. Gerken, K.-H. Meyer zum Büschenfelde (1999): The presence of high
amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBVinduced
immune response. J. Hepatol. 30, 353-358. IF: 9,264
36. K. Hildner, S. Finotto, C. Becker, J. F. Schlaak, P. Schirmacher, P. R. Galle, E. Märker-Hermann, M. F. Neurath
(1999): Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose
methotrexate in rheumatoid arthritis. Clin. Exp. Immunol. 118, 137-146. IF: 3,360
37. W. J. Mayet, A. Schwarting, A. P. Barreiros, J. F. Schlaak, M. F. Neurath (1999): Anti-PR-3 antibodies induce
endothelial IL-8 release. Eur. J. Clin. Invest. 29, 973-979. IF: 3,018
38. W. J. Mayet, E. Märker-Hermann, J. F. Schlaak, K.-H.Meyer zum Büschenfelde (1999): Irregular cytokine
pattern of CD4+ T lymphocytes in response to Staphylococcus aureus in patients with Wegener's
granulomatosis. Scand. J. Immunol. 49[6], 585-594. IF: 2,230
39. A. P. Barreiros, P. Schirmacher, R. Laufenberg-Feldmann, K.-H. Meyer zum Büschenfelde, J. F. Schlaak
(2000): The early immune response in the liver of BALB/c mice infected with S. typhimurium. Scand. J.
Immunol. 51[5], 472-478. IF: 2,230
40. T. Orth, M. Peters, J. F. Schlaak, F. Krummenauer, R. Wanitschke, W. J. Mayet, P. R. Galle, M. F. Neurath
(2000): Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month
pilot study. Am. J. Gastroenterol. 98[5]: 1201-1207. IF: 7,282
41. R. Atreya, J. Mudter, S. Finotto, J. Mullberg, T. Jostock, S. Wirtz, M. Schutz, B. Bartsch, M. Holtmann, C. Becker,
D. Strand, J. Czaja, J. F. Schlaak, H. A. Lehr, F. Autschbach, G. Schurmann, N. Nishimoto, K. Yoshizaki, H. Ito,
T. Kishimoto, P. R. Galle, S. Rose-John, M. F. Neurath (2000): Blockade of interleukin 6 transsignaling
suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and
experimental colitis in vivo. Nat. Med. 6[5], 583-588. IF: 22,462
42. P. Micke, K. M. Beeh, J. F. Schlaak, R.Buhl (2001). Oral supplementation with whey proteins increases plasma
glutathione levels of HIV-infected patients. Eur. J. Clin. Invest 31[2], 171-178. IF: 3,018
43. B. Strobl, V. Arulampalam, H. Is'harc, S. J. Newman, J. F. Schlaak, D. Watling, A.P.Costa-Pereira, F. Schaper, I.
Behrmann, K. C. Sheehan, R. D. Schreiber, F. Horn, P. C. Heinrich, I. M. Kerr (2001). A completely foreign
receptor can mediate an interferon-gamma-like response. EMBO J. 20[19], 5431-5442. IF: 9,205
44. J.F. Schlaak, A.P. Barreiros, S. Pettersson, P. Schirmacher, K.H. Meyer zum Büschenfelde, M.F. Neurath
(2001). Antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappaB abrogate fulminant septic
shock induced by S. typhimurium in mice. Scand. J. Immunol. 54[4], 396-403. IF: 2,230
45. F. Aberger, A. P. Costa-Pereira, J. F. Schlaak, T. M. Williams, R. F. O'Shaughnessy, G. Hollaus, I. M. Kerr, A.
M. Frischauf (2001). Analysis of Gene Expression Using High-Density and IFN-gamma-Specific Low-Density
cDNA Arrays. Genomics 77[1/2], 50-57. IF: 3,019
46. J. F. Schlaak, C. Schramm, K. Radecke, K.-H. Meyer zum Büschenfelde, G. Gerken. Sustained suppression of
HCV replication and inflammatory activity after interleukin-2 therapy in patients with HIV/Hepatitis C coinfection
(2002). J. Acquir. Immune. Defic. Syndr. 29[2], 145-148. IF: 4,425
47. A. P. Costa-Pereira, S. Tininini, B. Strobl, T. Alonzi, J. F. Schlaak, H. Is'harc, I. Gesualdo, S. J. Newman, I. M.
Kerr, V. Poli. Mutational switch of an IL-6 response to an interferon-gamma -like response (2002). P. Natl. Acad.
Sci. USA 99[12], 8043-8047. IF: 9,681
48. J.F. Schlaak, C.M.U. Hilkens, A.P. Costa-Pereira, B. Strobl, F. Aberger, A.M. Frischauf, I.M. Kerr (2002). Celltype
and donor-specific transcriptional responses to interferon-alpha – use of customised gene arrays. J. Biol.
Chem. 277[51], 49428-37. IF: 4,773
49. A.P. Barreiros, J.F. Schlaak, G. Gerken, P.R. Galle, H.F. Löhr. Interleukin-2 has no additional therapeutic
efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus
ribavirin (2003). Eur. J. Clin. Invest. 33(7):628-9. IF: 3,018
50. L. Strahle, D. Garcin, P. Le Mercier, J.F. Schlaak, D. Kolakofsky. Sendai virus targets inflammatory responses,
as well as the interferon-induced antiviral state, in a multifaceted manner (2003). J. Virol. 77(14):7903-13. IF:
5,402
51. C.M.U. Hilkens, J.F. Schlaak, I.M. Kerr. Differential Responses to IFN-alpha Subtypes in Human T Cells and
Dendritic Cells (2003). J. Immunol. 171(10):5255-63. IF: 5,788

52. A. Luik, S. Knapp, M. Thursz, H.C. Thomas, J.F. Schlaak. Autoregulatory role of Interleukin-10 in hepatitis C
patients treated with IFN-α (2004). J. Interf. Cytok. Res. 24(10): 585-593. IF: 3,063
53. M. Jones, A. Davidson, L. Hibbert, P. Grünewald, J.F. Schlaak, S. Ball, G.R. Foster, M. Jacobs. Dengue virus
inhibits alpha interferon signaling by reducing STAT2 expression (2005). J. Virol. 79(9):5414-20. IF: 5,402
54. T. Zoepf, E.J. Maldonado-Lopez, P. Hilgard, A. Dechene, M. Malago, C.E. Broelsch, J. F. Schlaak, G. Gerken.
Diagnosis of biliary strictures after liver transplantation: Which is the best tool? (2005). World J. Gastroenterol.
11(19):2945-8. IF: 2,471
55. S. Guan, H. Liu, D. Yang, M. Lu, M. Roggendorf, J. F. Schlaak. Establishment of a new low-density cDNA
macroarray and the application in the activity of IFN against HBV (2005). Chin J Exp Clin Virol. 19(3):236-9.
56. T. Zoepf, E. Maldonado-Lopez, P. Hilgard, J. F. Schlaak, M. Malago, C.E. Broelsch, U. Treichel, G. Gerken.
Endoscopic therapy of posttransplant biliary stenoses after right-sided adult living donor liver transplantation
(2005). Clin. Gastroenterol. Hepatol. 3(11):1144-9. IF: 5,627
57. Y. Erim, M. Beckmann, C. Valentin-Gamazo, M. Malago, A. Frilling, J. F. Schlaak, G. Gerken, C. E. Broelsch, W.
Senf. Quality of Life and Psychiatric Complications after Adult Living Donor Liver Transplantation (2006). Liver
Transpl., 12(12):1782-90. IF: 3,386
58. S. Guan, M. Lu, P. Grünewald, M. Roggendorf, G. Gerken, J. F. Schlaak. The interferon-alpha response in HBVtransfected
HepG2.2.15 cells is partially restored by lamivudine treatment (2007). World J. Gastroenterol.,
13(2): 234-241. IF: 2,471
59. M. Bockhorn, A. Frilling, T. Benkö, J. Best, S.-Y. Sheu, M. Trippler, J. F. Schlaak, Broelsch CE. Tri-iodothyronine
as a stimulator of liver regeneration after partial and subtotal hepatectomy (2007). Eur. Surg. Res., 39(1):58-63.
IF: 0,932
60. M. Bockhorn, S. Schöllmann, B. Opitz, G.C. Sotiropoulos, S.-Y. Sheu, E. Niehues, M. Trippler, A. Frilling, C.E.
Broelsch, J. F. Schlaak. VEGF does not improve liver regeneration and survival after 90% subtotal liver
resection (2007), Hepatol. Res., 37(5):353-9. IF: 1,540
61. M. Bockhorn, M. Goralski, D. Prokofiev, P. Dammann, P. Grünewald, M. Trippler, M. Kamler, A. Frilling, C. E.
Broelsch, J. F. Schlaak. VEGF is important for early liver regeneration after partial hepatectomy (2007). J. Surg.
Res., 138(2):291-9. IF: 2,247
62. J. Wu, M. Lu, Z. Meng, M. Trippler, M. Roggendorf, G. Gerken, J. F. Schlaak. TLR-mediated control of HBV
replication by non-parenchymal liver cells in mice (2007). Hepatology, 46(6):1769-1778. IF: 11,665
63. M. Bockhorn, T. Benkö, B. Opitz, S.-Y. Sheu, G. C. Sotiropoulos, J. F. Schlaak, C. E. Broelsch, H. Lang. Impact
of hepatic vein deprivation on liver regeneration and function after major hepatectomy (2008). Langenbeck
Arch. Surg., 393(4):527-33. IF: 1,807
64. Y. Erim, M. Beckmann, C. Valentin-Gamazo, M. Malago, A. Frilling, J. F. Schlaak, G. Gerken, C. E. Broelsch, W.
Senf. Selection of donors for adult living-donor liver donation: results of the assessment of the first 205 donor
candidates (2008). Psychosomatics, 49(2):143-51. IF: 2,123
65. R. Broering, J. Wu, Z. Meng, P. Hilgard, M. Lu, M. Trippler, A. Szczeponek, G. Gerken, J. F. Schlaak. TLR
stimulated non-parenchymal liver cells are potent suppressors of HCV replication (2008). J. Hepatol., 48(6):914-
22. IF: 9,264
66. M. Bockhorn, C. D. Fingas, Y. Gu, U. Rauen, E. Niehues, A. Frilling, C. E. Broelsch, J. F. Schlaak.
Erythropoietin improves liver regeneration and survival in rat models of extended liver resection and living donor
liver transplantation (2008). Transplantation, 86(11):1578-85. IF: 4,003
67. J.-P. Sowa, J. Best, T. Benko, M. Bockhorn, Y. Gu, A. Bucchi, G. Gerken, U. Rauen, J. F. Schlaak. The extent
of liver resection modulates the activation of transcription factors and the production cytokines that are involved
in liver regeneration (2008). World. J. Gastroenterol., 14(46):7093-100. IF: 2,471
68. Z. Meng, S. Qiu, X. Zhang, J. Wu, T. Schreiter, Y. Xu, D. Yang, M. Roggendorf, J. F. Schlaak, M. Lu. Inhibition
of woodchuck hepatitis virus gene expression in primary hepatocytes by siRNA enhances the cellular gene
expression (2009). Virology, 384(1):88-96. IF: 3,351
69. J. Wu, Z. Meng, J. Min, R. Pei, M. Trippler, R. Broering, A. Bucchi, J.-P. Sowa, U. Dittmer, D. Yang, M.
Roggendorf, G. Gerken, M. Lu, J. F. Schlaak. HBV suppresses Toll-like receptor mediated innate immune
responses in murine parenchymal and non-parenchymal liver cells (2009). Hepatology, 49(4):1132-40. IF:
11,665

70. B. Wang, M. Trippler, M. Lu, R. Broering, G. Gerken, J. F. Schlaak. Toll-like receptor activated human and
murine hepatic stellate cells are potent regulators of hepatitis C virus replication (2009). J. Hepatol.
2009;51(6):1037-45. IF: 9,264
71. X. Zhang, Z. Meng, S. Qiu, Y. Xu, D. Yang, J. F. Schlaak, M. Roggendorf, M. Lu. Lipopolysaccharide induced
innate immune responses in primary hepatocytes inhibit woodchuck hepatitis virus replication via interferonindependent
pathways (2009). Cell. Microbiol. 11(11):1624-37. IF: 5,458
72. M.R. Rani, Y. Xu, J. C. Lee, J. Shrock, A. Josyula, J. F. Schlaak, S. Chakraborthy, N. Ja, R.M. Ransohoff, R. A.
Rudick. Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta (2009). Ann. N.
Y. Acad. Sci. 1182:58-68. IF: 3,155
73. J. Wu, Z. Meng, M. Jiang, E. Zhang, M. Trippler, R. Broering, A. Bucchi, F. Krux, U. Dittmer, D. Yang, M.
Roggendorf, G. Gerken, M. Lu, J. F. Schlaak. TLR induced innate immune response in non-parenchymal liver
cells are cell type-specific (2010). Immunology. 129 (3), 363-374. IF: 3,276
74. Y. Erim, S. Tagay, M. Beckmann, S. Bein, V. Cicinatti, S. Beckebaum, W. Senf, J. F. Schlaak. Depression and
Protective Factors of Mental Health in People with Hepatitis C: a questionnaire survey (2010). Int. J. Nurs. Stud.
47(3):342-349. IF: 2,178
75. T. Benkö, S. Frede, Y. Gu, J. Best, H.A. Baba, J. F. Schlaak, H. de Groot, J. Fandrey, U. Rauen. Glycine
pretreatment ameliorates liver injury after partial hepatectomy in the rat (2010). J. Invest. Surg., 23(1):12-20. IF:
1,091
76. R. Broering, M. Trippler, M. Jiang, M. Lu, G. Gerken, J. F. Schlaak. The interferon stimulated gene 15 functions
as a proviral factor for the hepatitis C virus and as an attenuator of the IFN response in hepatocytes (2010). Gut,
59(8):1111-9. IF: 10,111
77. P. Burbelo, J. Kovacs, K. Ching, A. Issa, M. Iadarola, J. F. Schlaak, H. Masur, M. Polis, S. Kottilil. Proteomewide
anti-HCV and anti-HIV antibody profiling for predicting and monitoring response to HCV treatment in HIV
co-infected patients (2010). J. Infect. Dis., 15;202(6):894-8. IF: 6,410
78. J. Ertle, A. Dechêne, J.-P. Sowa, V. Penndorf, K. Herzer, G. Kaiser, J. F. Schlaak, G. Gerken, W.-K. Syn, A.
Canbay. Nonalcoholic fatty liver disease progresses to HCC in the absence of apparent cirrhosis (2011). Int. J.
Cancer. 1;128(10):2436-43. IF: 5,444
79. X. Zhang, Z. Ma, E. Zhang, M. Jiang, J. F. Schlaak, M. Roggendorf, M. Lu. Modulation of HBV replication and
hepatocyte differentiation by MicroRNA-1 (2011). Hepatology, 53(5):1476-85. IF: 11,665
80. A. Katsounas, M. Trippler, S. Bein, S. Kottilil, R. A. Lempicki, G. Gerken, J. F. Schlaak. Altered Expression of
SHIP, a Toll-like Receptor 2 and 4 Pathway Inhibitor, is Associated with the Severity of Liver Fibrosis in Chronic
Hepatitis C Virus Infection (2011). J. Infect. Dis., 204(8):1181-5. IF: 6,410
81. M. Montag, R. Broering, J. Min, M. Lu, J.-P. Sowa, G. Gerken, J. F. Schlaak. Corticosteroids shift the response
pattern of the hepatic innate immune system from an inflammatory to an anti-inflammatory state (2011). Int.
Immunol., 23(9):537-44. IF: 3,415
82. T.C. Lauenstein, T.A. Heusner, M. Hamami, J. Ertle, J. F. Schlaak, G. Gerken, A. Bockisch, G. Antoch.
Radioembolization of hepatic tumors: flow redistribution after the occlusion of intrahepatic arteries (2011). Rofo,
183(11):1058-1064. IF: 2,758
83. J. Wu, M.F. Chen, Y.C. Xia, Y. Guo, Y. Lin, C. Sun, C.Y. Zhang, Y. Chen, S.P. Liu, Y.H. Hao, M. Lu, J.F.
Schlaak., D.L. Yang. Toll-like receptor dependent innate immune responses by primary mouse hepatocytes and
its control of HBV replication (2011). Chin. J. of Hepatol., 19(11):838-42.
84. A. Katsounas, M. Trippler, B. Wang, M. Polis, R. A. Lempicki, S. Kottilil, G. Gerken, J. F. Schlaak. CCL5 is a
marker for early fibrosis in chronic hepatitis C and is regulated by Toll-like receptor 3 signaling and interferon-α
therapy (2012). J. Viral Hep., 19(2):128-37. IF: 4,088
85. S. Naggie, A. Osinusi, A. Katsounas, E. Hermann, R. Lempicki, J.F. Schlaak, A. Thompson, P. Clark, M.
Trippler, K. Patel, B. Shivakumar, A. Muir, J. McHutchison, D. Goldstein, H. Masur, M. A. Polis, S. Kottilil.
Dysregulation Of Host Innate Immunity In HIV/HCV Genotype 1 Infected IL28B CT/TT Haplotype Patients
Associated With Depressed Viral Kinetics And Therapeutic Response (2012). Hepatology. 56(2):444-54. IF:
11,665
86. A. Osinusi, S. Naggie, S. Poonia, M. Trippler, Z. Hu, J. F. Schlaak, D. Fishbein, H. Masur, M. Polis, S. Kottilil.
ITPA Gene Polymorphisms Significantly Affect Hemoglobin Decline and Treatment Outcomes in HIV/HCV Coinfected
Patients (2012). J. Med. Virol., 84(7):1106-14. IF: 2,820

87. A. Katsounas, M. Trippler, S. Kottilil, R. A. Lempicki, C. H. Lane, G. Gerken, J. F. Schlaak. Cytokine/Chemokine
patterns connect various host and viral characteristics with clinics during chronic hepatitis C (2012). Eur. J. Med.
Res., 11;17(1):9. IF: 0,978
88. J. Theysohn, J. F. Schlaak, S. Müller, J. Ertle, T. W. Schlosser, A. Bockisch, T. C. Lauenstein. Selective internal
radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after Sorafenib
administration (2012). J. Vasc. Int. Radiol., 23(7):949-52. IF: 2,075
89. X. Zhang, Z. Ma, H. Liu, J. Liu, Z. Meng, R. Broering, D. Yang, J. F. Schlaak, M. Roggendorf, M. Lu. Role of
Toll-like receptor 2 in the immune response against Hepadnaviral infection (2012). J. Hepatol., 57(3):522-8. IF:
9,264
90. J. F. Schlaak, M. Trippler, Y. Erim, B. Kis, B. Wang, N. Scherbaum, G. Gerken. Common pathways in
endogenous depression and depression induced by IFN-α therapy for chronic hepatitis C (2012). PLoS One,
7(6):e38668. IF: 4,092
91. G. Ren, S. Esser, C. Jochum, J. F. Schlaak, G. Gerken, D. Schadendorf, U. Dittmer, G. Wu, Z. Yuan, J. Timm.
IL-21 augments the HBV-specific CD8+T cell response in vitro in patients coinfected with HIV-1 (2012). AIDS, in
press. IF: 6,245
92. J. M. Theysohn, S. Müller, J. F. Schlaak, J. Ertle, T. W. Schlosser, A. Bockisch, T. C. Lauenstein. Selective
Internal Radiation Therapy (SIRT) of hepatic tumors: how to deal with the cystic artery (2012). Cardiovasc
Intervent Radiol., in press. IF: 2,093
93. J. M. Ertle, D. Heider, M. Wichert, B. Keller, R. Kueper, P. Hilgard, G. Gerken, J. F. Schlaak. Combination of
Alphafetoprotein and Des-Gamma-Carboxy Prothrombin is superior in detection of Hepatocellular Carcinoma
(2013). Digestion, 87:121-131. IF: 2,046
94. A. Katsounas, J. J. Hubbard, C. H. Wang, X. Zhang, D. Dou, B. Shivakumar, S. Winter, J. F. Schlaak, R. A.
Lempicki, H. Masur, M. Polis, S. Kottilil, A. Osinusi. High Interferon Stimulated Gene ISG-15 Expression Affects
HCV Treatment Outcome in HIV/HCV Coinfected Patients (2013). J. Med. Virol., 85(6):959-63. IF: 2,820
95. M. Schuchmann, J.M. Kittner, J. F. Schlaak, D. Klass, N. Dikopolous, C. Eisenbach, T. Berg, C. Trautwein, R.
Günther, S. Zeuzem, R. Gösseringer, A. Ehrlich, K. Neumann, D. Wachtlin, M.F. Sprinzl, T. Zimmermann, W.O.
Böcher, P.R. Galle. Viral efficacy and safety of all-trans retinoic acid in HCV patients with previous non-response.
Dig. Liv. Dis., in press. IF: 3,054
96. F. A. Tucci, R. Bröring, P. Johansson, J. F. Schlaak, R. Küppers. B cells in chronically hepatitis C virus-infected
individuals lack a virus-induced mutation signature in the TP53, CTNNB1, and BCL6 genes. J. Virol., in press.
IF: 5,402
97. D. A. Megger, T. Bracht, M. Kohl, M. Ahrens, F. Weber, A.-C. Hoffmann, C. Stephan, M. Eisenacher, J. F.
Schlaak, H. A. Baba, H. E. Meyer, B. Sitek. Combining different quantification techniques in proteomics-based
clinical studies reveals confident hepatocellular carcinoma biomarker candidates. Mol. Cell. Proteomics, in
press. IF: 7,398
98. Kohl M, Megger DA, Trippler M, Meckel H, Ahrens M, Bracht T, Weber F, Hoffmann AC, Baba HA, Sitek B,
Schlaak JF, Meyer HE, Stephan C, Eisenacher M. A practical data processing workflow for multi - OMICS
projects. Biochim Biophys Acta. 2013 Mar 14. doi:pii: S1570-9639(13)00092-7. 10.1016/j.bbapap.2013.02.029.
IF: 3,635
99. I. Nel, H. A. Baba, J. Ertle, F. Weber, B. Sitek, M. Eisenacher, H. E. Meyer, J. F. Schlaak, A.-C. Hoffmann.
Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular
carcinoma. Translat. Oncol., in press. IF: 3,393
100. M. Jiang, R. Broering, M. Trippler, J. Wu, E. Zhang, X. Zhang, G. Gerken, M. Lu, J. F. Schlaak. MicroRNA-155
controls toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. J. Viral Hep., in press.
IF: 4,088
101. R. Pei, B. Qin, X. Zhang, W. Zhu, T. Kemper, Z. Ma, M. Trippler, J. F. Schlaak, X. Chen, M. Lu. Interferoninduced
protein with tetratricopeptide repeats 1 and 2 are cellular factors that limit hepatitis B virus replication. J.
Innate Immun., in press. IF: 4,209

III. Fallmitteilungen
1. T. Wölfel, P. Schirmacher, J. F. Schlaak, P. Knolle, H.-P. Dienes, W. Dippold, K.-H. Meyer zum Büschenfelde,
G. Gerken. Sustained elimination of hepatitis B virus from serum induced in a patient with chronic hepatitis B and
advanced human immunodeficiency virus infection (1994). Clin. Investig. 72, 1030-1036.
2. C. Schramm, J.F. Schlaak, P.R. Galle. Rapid development of Epstein-Barr virus-associated Hodgkin's disease
after cessation of foscarnet therapy in an HIV-infected patient (2000). Int.J.STD AIDS 11[9], 609-610.
3. G.C. Sotiropoulos, J. Treckmann, A. Radtke, G. Antoch, E. Brokalaki, J.F. Schlaak, C. E. Broelsch. Arterioportal
fistula complicating endoscopic retrograde cholangiography (2005). Endoscopy 37[1], 93-4.
4. A. Katsounas, C. Jochum, A. Canbay, J.F. Schlaak, W. Gerlich, G. Gerken. Core Promoter Mutant HBV Nonresponding
To Adefovir after Viral Breakthrough on Lamivudine: Rapid Virologic Response to Tenofovir Plus
Lamivudine in a Cirrhotic Patient (2008). Eur J Med Res. 27;13(10):472-5.
5. A. Abendroth, R. Klein, J.F. Schlaak, K.A. Metz, G.J. Dobos, J. Langhorst. Imposanter Befund einer Melanosis
coli nach jahrzehntelangem Abusus von Anthrachinonderivaten - Ein Risikofaktor für kolorektale Neoplasien
(2009)? Z. Gastroent. 47 (6), 579-82.
IV. Übersichtsarbeiten
1. P. Knolle, H. Löhr, U. Treichel, H.-P. Dienes, A. Lohse, J. F. Schlaak, G.Gerken (1995): Parenchymal and
nonparenchymal liver cells and their interaction in the local immune response. Z. f. Gastroenterol., 33, 613-620.
2. J. F. Schlaak, H. Koehler, G.Gerken (1996): Hepatitis G virus: an old, but newly discovered hepatotropic virus. Is
it of interest for the nephrologist ?. Nephrol.Dial.Transplant. 11[8], 1522-1523.
3. J. F. Schlaak, G. Gerken (1997): Aktuelle Strategie in der Diagnostik und Therapie der chronischen
Virushepatitiden. Tägl. prax., 38, 515-526.
4. J. F. Schlaak, G. Gerken (1997): Diagnose und Therapie der chronischen Virushepatitiden. Internist. prax., 37,
519-530.
5. J. F. Schlaak (1997): Virushepatitiden – Verlauf und extrahepatische Manifestationen. Krankenhaus Arzt, 70,
8-9.
6. J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden. Differentialdiagnostik und Therapie. Fortschr.
Med.115:34-36.
7. J. F. Schlaak, G. Gerken (1997): G. Chronische Hepatitiden. Differentialdiagnose der Hepatitis C. Fortschr.
Med.115:38-39.
8. J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden. Differentialdiagnose der Hepatitis B, D und G.
Fortschr. Med.115:44-46.
9. J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden. Diagnose der autoimmunen Lebererkrankungen.
Fortschr. Med. 115:33-34.
10. J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden: Therapie der chronischen Virushepatitiden. Fortschr.
Med. 115:48-50.
11. J. F. Schlaak, G. Gerken (1997): Chronische Hepatitiden: Therapie der autoimmunen Leberkrankungen.
Fortschr. Med. 115:52-53.
12. J. Wu, R. Bröring, J. F. Schlaak. The role of the innate immune system of the liver in the control of HBV and
HCV (2008). Virologica Sinica 23 (2): 116-123.
13. J. Ertle, T. Lauenstein, J. F. Schlaak. Benefit of using TARE-Y90 comparing with TACE in the management of
primary and secondary liver tumors (2011). Eur. J. Clin. Med. Oncol., 3(1): 44-50.
14. A. Katsounas, J. F. Schlaak, R. A. Lempicki. CCL5: A Double-edged Sword in Host Defense against the
Hepatitis C Virus (2011). Int. Rev. Immunol., 30(5-6):366-78. IF: 2,641

15. R. Broering, M. Lu, J. F. Schlaak. Toll-like receptors in liver health and disease: mechanisms and therapeutic
potential (2011). Clin. Science, 1;121(10):415-26. IF: 4,613
16. X. Zhang, A. Kraft, R. Broering, J. F. Schlaak, U. Dittmer, M. Lu. Preclinical development of TLR ligands as
drugs for the treatment of chronic viral infections (2012). Exp. Opin. Curr. Drug Disc., 7(7):597-611.
17. J. Ertle, G. Gerken, J. F. Schlaak. Lokalablative Therapien zur Behandlung des hepatozellulären Karzinoms
(2012). Der Gastroenterologe, in press.
18. J. Ertle, G. Gerken, J. F. Schlaak. Radioembolisation bei forgeschrittenem hepatozellulären Karzinom.
Viszeralmedizin (2012). Viszeralmed. 28(5), 311-16.
19. K. Gibbert, J. F. Schlaak, D. L. Yang, U. Dittmer. Interferon alpha subtypes: Distinct Biological activities in antiviral
therapy (2012). Br. J. Pharm., in press.
V. Buchbeiträge
1. J. F. Schlaak, G. Gerken (1997): HCV-Koinfektionen. In: Hepatitis C, Häussinger, Niederau (Hrsg.), Blackwell
Wissenschafts-Verlag, Berlin, Wien.
2. J. F. Schlaak, G. Gerken (2001): HCV-Koinfektionen. In: Hepatitis C, Häussinger, Niederau (Hrsg.), Blackwell
Wissenschafts-Verlag, Berlin, Wien.
3. J. F. Schlaak, G. Gerken (2003): Das primäre Leberzellkarzinom als Folge der Hepatitis B- und C-Infektion. In:
Virushepatitis als Berufskrankheit, Selmair, Manns (Hrsg.), Ecomed Verlag, Landsberg.
4. J. F. Schlaak, G. Gerken (2004): Management of IL-2 toxicity. In: Immunotreatment and gene therapy of HIV
infection, Hengge, Kabelitz (Hrsg.), Unimed Verlag, Bremen.
5. A. Canbay, J. F. Schlaak, G. Gerken, R. Gieseler (2007). Dysregulated Apoptosis in Liver Diseases. In : Cell
apoptosis: Regulation and environmental factors, (Schultz (Hrsg.), Nova Science Publishers, Inc, New York,
USA.
6. J. F. Schlaak, G. Gerken (2007): Das primäre Leberzellkarzinom als Folge der Hepatitis B- und C-Infektion. In:
Virushepatitis als Berufskrankheit, Selmair, Manns (Hrsg.), Ecomed Verlag, Landsberg.
7. C. Jochum, J.F. Schlaak (2010). Hepatitis C: Symptoms, Diagnosis and Treatment, pp. 135-158 In : Advances
in Medicine and Biology, Vol. 9, (Berhardt (Hrsg.), Nova Science Publishers, Inc, New York, USA.
8. R. Bröring, M. Lu, J.F. Schlaak (2011). Toll like receptors in chronic viral hepatitis – friend and foe. In: Viral
Hepatitis, ISBN 979-953-307-103-8, InTech, Rijeka, Croatia.